0R29.L
Intuitive Surgical, Inc. [0R29.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0R29.L Stock Summary
In the News
0R29.L Financial details
Company Rating
Strong Buy
Market Cap
135.65B
Income
1.8B
Revenue
7.12B
Book val./share
37.79
Cash/share
14.83
Dividend
-
Dividend %
-
Employees
13.68K
Optionable
No
Shortable
Yes
Earnings
18 Apr 2024
P/E
78.1
Forward P/E
-
PEG
20.9
P/S
16.99
P/B
9.45
P/C
24.8
P/FCF
92.59
Quick Ratio
4.52
Current Ratio
5.31
Debt / Equity
0.01
LT Debt / Equity
0
-
-
EPS (TTM)
5.11
EPS next Y
-
EPS next Q
-
EPS this Y
37.63%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
5.17%
Revenue last 5Y
9.73%
Revenue Q/Q
10.59%
EPS Q/Q
45.76%
-
-
-
-
SMA20
-2.57%
SMA50
-1.04%
SMA100
23.45%
Inst Own
-
Inst Trans
-
ROA
10%
ROE
13%
ROC
0.13%
Gross Margin
67%
Oper. Margin
25%
Profit Margin
22%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
232.27-402.02
52W High
-8.52%
52W Low
+58.52%
RSI
39
Rel Volume
27.9
Avg Volume
4.89K
Volume
136.4K
Perf Week
-6.11%
Perf Month
-6.52%
Perf Quarter
42.19%
Perf Half Y
32.76%
-
-
-
-
Beta
1.385
-
-
Volatility
6.52%, 8.15%
Prev Close
-1.31%
Price
367.7571
Change
-1.67%
0R29.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 12.94 | 12.42 | 16.04 | 17.49 | 20.29 | |
| Net income per share | 3.98 | 3.02 | 4.79 | 3.72 | 5.12 | |
| Operating cash flow per share | 4.62 | 4.23 | 5.87 | 4.19 | 4.7 | |
| Free cash flow per share | 3.39 | 3.26 | 4.87 | 2.69 | 1.67 | |
| Cash per share | 9.31 | 14.56 | 11.81 | 11.59 | 14.87 | |
| Book value per share | 23.87 | 27.73 | 33.42 | 31.04 | 37.89 | |
| Tangible book value per share | 22.72 | 26.62 | 32.4 | 30.12 | 37.15 | |
| Share holders equity per share | 23.87 | 27.73 | 33.42 | 31.04 | 37.89 | |
| Interest debt per share | 0.02 | 0.06 | 0.06 | 0.07 | 0.26 | |
| Market cap | 348.46B | 353.29B | 128.66B | 95.26B | 118.6B | |
| Enterprise value | 347.37B | 351.75B | 127.46B | 93.78B | 115.94B | |
| P/E ratio | 252.64 | 333.11 | 75.48 | 72.04 | 65.96 | |
| Price to sales ratio | 77.81 | 81.06 | 22.53 | 15.31 | 16.65 | |
| POCF ratio | 218.03 | 237.94 | 61.58 | 63.9 | 71.92 | |
| PFCF ratio | 297.17 | 309.01 | 74.12 | 99.4 | 202.78 | |
| P/B Ratio | 42.17 | 36.3 | 10.81 | 8.63 | 8.91 | |
| PTB ratio | 42.17 | 36.3 | 10.81 | 8.63 | 8.91 | |
| EV to sales | 77.56 | 80.71 | 22.32 | 15.07 | 16.27 | |
| Enterprise value over EBITDA | 220.59 | 264.25 | 59.61 | 48.57 | 52.65 | |
| EV to operating cash flow | 217.35 | 236.9 | 61 | 62.9 | 70.31 | |
| EV to free cash flow | 296.24 | 307.66 | 73.42 | 97.85 | 198.23 | |
| Earnings yield | 0 | 0 | 0.01 | 0.01 | 0.02 | |
| Free cash flow yield | 0 | 0 | 0.01 | 0.01 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0.01 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0.01 | |
| Net debt to EBITDA | -0.69 | -1.16 | -0.56 | -0.77 | -1.21 | |
| Current ratio | 4.53 | 6.86 | 5.08 | 4.4 | 4.76 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 1.16 | 1.4 | 1.23 | 1.13 | 0.92 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.12 | 0.13 | 0.12 | 0.14 | 0.14 | |
| Intangibles to total assets | 0.04 | 0.04 | 0.03 | 0.03 | 0.02 | |
| Capex to operating cash flow | -0.27 | -0.23 | -0.17 | -0.36 | -0.65 | |
| Capex to revenue | -0.1 | -0.08 | -0.06 | -0.09 | -0.15 | |
| Capex to depreciation | -2.13 | -1.21 | -1.12 | -1.5 | -2.45 | |
| Stock based compensation to revenue | 0.08 | 0.09 | 0.08 | 0.08 | -0.24 | |
| Graham number | 46.26 | 43.42 | 60 | 50.96 | 66.07 | |
| ROIC | 0.15 | 0.09 | 0.14 | 0.12 | 0.12 | |
| Return on tangible assets | 0.15 | 0.1 | 0.13 | 0.11 | 0.12 | |
| Graham Net | 7.38 | 12.78 | 10.01 | 9.87 | 13.26 | |
| Working capital | 3.63B | 5.66B | 4.7B | 4.83B | 6.23B | |
| Tangible asset value | 7.87B | 9.35B | 11.54B | 10.71B | 13.05B | |
| Net current asset value | 3.21B | 5.22B | 4.24B | 4.39B | 5.76B | |
| Invested capital | 0 | 0 | 0 | 0 | 0.01 | |
| Average receivables | 689.35M | 645.35M | 769.25M | 983.15M | 1.17B | |
| Average payables | 112.1M | 102.55M | 101.4M | 134.1M | 167.85M | |
| Average inventory | 502.25M | 598.5M | 594.3M | 740.15M | 1.06B | |
| Days sales outstanding | 52.58 | 54.06 | 57.08 | 62.96 | 64.94 | |
| Days payables outstanding | 32.67 | 19.6 | 24.99 | 26.37 | 28.76 | |
| Days of inventory on hand | 157.53 | 144.45 | 121.07 | 160.22 | 186.05 | |
| Receivables turnover | 6.94 | 6.75 | 6.39 | 5.8 | 5.62 | |
| Payables turnover | 11.17 | 18.63 | 14.6 | 13.84 | 12.69 | |
| Inventory turnover | 2.32 | 2.53 | 3.01 | 2.28 | 1.96 | |
| ROE | 0.17 | 0.11 | 0.14 | 0.12 | 0.14 | |
| Capex per share | -1.23 | -0.97 | -0.99 | -1.5 | -3.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.71 | 4.84 | 5 | 4.96 | 5.48 | |
| Net income per share | 0.93 | 1.01 | 1.2 | 1.18 | 1.72 | |
| Operating cash flow per share | 1.25 | 1.06 | 1.9 | 1.12 | 0.62 | |
| Free cash flow per share | 0.86 | 0.51 | 1.39 | 0.39 | -0.61 | |
| Cash per share | 11.74 | 13.4 | 16.53 | 18.41 | 14.83 | |
| Book value per share | 31.45 | 32.03 | 33.85 | 35.65 | 37.79 | |
| Tangible book value per share | 30.52 | 31.13 | 32.95 | 34.78 | 37.06 | |
| Share holders equity per share | 31.45 | 32.03 | 33.85 | 35.65 | 37.79 | |
| Interest debt per share | 0.07 | 0.36 | 0.66 | 0.97 | 0.26 | |
| Market cap | 94.03B | 89.25B | 120.34B | 102.9B | 118.91B | |
| Enterprise value | 92.54B | 87.1B | 116.9B | 99.3B | 116.25B | |
| P/E ratio | 72.35 | 62.8 | 71.49 | 61.89 | 49.04 | |
| Price to sales ratio | 56.82 | 52.62 | 68.53 | 59.01 | 61.66 | |
| POCF ratio | 214.73 | 240.3 | 180.77 | 261.84 | 542.96 | |
| PFCF ratio | 313.23 | 503.36 | 246.9 | 752.77 | -549.23 | |
| P/B Ratio | 8.52 | 7.96 | 10.13 | 8.21 | 8.94 | |
| PTB ratio | 8.52 | 7.96 | 10.13 | 8.21 | 8.94 | |
| EV to sales | 55.92 | 51.35 | 66.58 | 56.95 | 60.28 | |
| Enterprise value over EBITDA | 193.32 | 181.35 | 208.57 | 172.88 | 206.04 | |
| EV to operating cash flow | 211.34 | 234.53 | 175.61 | 252.68 | 530.81 | |
| EV to free cash flow | 308.28 | 491.27 | 239.85 | 726.42 | -536.94 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0.01 | 0.02 | 0.03 | 0.01 | |
| Debt to assets | 0 | 0.01 | 0.02 | 0.02 | 0.01 | |
| Net debt to EBITDA | -3.11 | -4.46 | -6.13 | -6.27 | -4.72 | |
| Current ratio | 4.4 | 5.26 | 5.22 | 5.31 | 4.76 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 1.35 | 1.05 | 1.58 | 0.95 | 0.36 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.15 | 0.14 | 0.14 | 0.14 | 0.13 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | |
| Capex to operating cash flow | -0.31 | -0.52 | -0.27 | -0.65 | -1.99 | |
| Capex to revenue | -0.08 | -0.11 | -0.1 | -0.15 | -0.23 | |
| Capex to depreciation | -1.3 | -2.09 | -1.83 | -2.36 | -3.82 | |
| Stock based compensation to revenue | 0.08 | 0.08 | 0.08 | 0.09 | -0.29 | |
| Graham number | 25.59 | 27.04 | 30.22 | 30.79 | 38.26 | |
| ROIC | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | |
| Return on tangible assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | |
| Graham Net | 10 | 12 | 14.64 | 16.16 | 13.23 | |
| Working capital | 4.83B | 5.57B | 6.49B | 7.23B | 6.23B | |
| Tangible asset value | 10.71B | 10.9B | 11.56B | 12.23B | 13.05B | |
| Net current asset value | 4.39B | 5.12B | 6.09B | 6.81B | 5.76B | |
| Invested capital | 0 | 0.01 | 0.02 | 0.03 | 0.01 | |
| Average receivables | 1.02B | 1.07B | 1.05B | 1B | 1.12B | |
| Average payables | 155.6M | 155.55M | 181.9M | 197.95M | 192.45M | |
| Average inventory | 865.15M | 919.9M | 975.9M | 1.08B | 1.18B | |
| Days sales outstanding | 58.37 | 56.11 | 53.24 | 49.69 | 59.16 | |
| Days payables outstanding | 24.23 | 25.25 | 30.7 | 30.63 | 26.09 | |
| Days of inventory on hand | 147.2 | 145.68 | 154.51 | 179.14 | 168.77 | |
| Receivables turnover | 1.54 | 1.6 | 1.69 | 1.81 | 1.52 | |
| Payables turnover | 3.71 | 3.56 | 2.93 | 2.94 | 3.45 | |
| Inventory turnover | 0.61 | 0.62 | 0.58 | 0.5 | 0.53 | |
| ROE | 0.03 | 0.03 | 0.04 | 0.03 | 0.05 | |
| Capex per share | -0.39 | -0.55 | -0.51 | -0.73 | -1.24 |
0R29.L Frequently Asked Questions
What is Intuitive Surgical, Inc. stock symbol ?
Intuitive Surgical, Inc. is a US stock , located in Sunnyvale of Ca and trading under the symbol 0R29.L
What is Intuitive Surgical, Inc. stock quote today ?
Intuitive Surgical, Inc. stock price is $367.7571 today.
Is Intuitive Surgical, Inc. stock public?
Yes, Intuitive Surgical, Inc. is a publicly traded company.
Company Profile
- Volume Average 4.89K
- Market Capitalization 135.65B
- Employee 13.68K
- CEO Dr. Gary S. Guthart Ph.D.
- Headquarters Sunnyvale,CA,US
- IPO Date 2014-11-07
-
Website
https://www.intuitive.com 
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
